IP Library Patent Application 12851417
Patent Application
App. No. 12/851,417

Combination Therapy For Modulating The Human Sexual Response

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/851,417
Abstract

The invention is directed to compositions and methods for modulating the human sexual response. The compositions comprise two or more pharmaceutically active agents which preferably include an alpha-adrenergic antagonist and a phosphodiesterase inhibitor.

Claims (16)

1 . A method for treating male impotence comprising administering to the gastrointestinal tract of a subject, a tablet or capsule comprising an alpha-adrenergic antagonist and a dopaminergic agonist and having a disintegration time of less than about twenty minutes, wherein the dopaminergic agonist is apomorphine and the alpha-adrenergic antagonist is selected from the group consisting of phentolamine, phentolamine hydrochloride and phentolamine mesylate.

2 . The method of claim 1 , wherein the tablet or capsule comprises from about 5 mg to about 100 mg phentolamine.

3 . The method of claim 2 , wherein the tablet or capsule comprises about 20 mg phentolamine.

4 . The method of claim 2 , wherein the tablet or capsule comprises about 40 mg phentolamine.

5 . The method of claim 2 , wherein the tablet or capsule comprises about 60 mg phentolamine.

6 . The method of claim 1 , wherein the tablet or capsule has a disintegration time of less than about ten minutes.

7 . The method of claim 1 , wherein the tablet or capsule has a disintegration time of less than about one minute.

8 . The method of claim 1 , wherein the tablet or capsule is effective to improve sexual responsiveness in from about 1 minute to about 60 minutes following administration.

9 . The method of claim 1 , wherein the tablet or capsule comprises apomorphine and from about 5 mg to about 100 mg phentolamine mesylate and has a disintegration time of less than about twenty minutes.

10 . The method of claim 9 , wherein the tablet or capsule has a disintegration time of less than about ten minutes.

11 . The method of claim 10 , wherein the tablet or capsule has a disintegration time of less than about one minute.

12 . The method of claim 9 , wherein the tablet or capsule is effective to improve sexual responsiveness in from about 1 minute to about 60 minutes following administration.

13 . The method of claim 1 , wherein the tablet or capsule comprises apomorphine and about 40 mg phentolamine mesylate and has a disintegration time of less than about twenty minutes.

14 . The method of claim 13 , wherein the tablet or capsule has a disintegration time of less than about ten minutes.

15 . The method of claim 13 , wherein the tablet or capsule has a disintegration time of less than about one minute.

16 . The method of claim 13 , wherein the tablet or capsule is effective to improve sexual responsiveness in from about 1 minute to about 60 minutes following administration.